BioNTech and Bristol Myers Squibb Report Phase 2 Pumitamig Data
The companies reported global Phase 2 data for pumitamig in advanced NSCLC after progression on immunotherapy plus chemotherapy.
The companies reported global Phase 2 data for pumitamig in advanced NSCLC after progression on immunotherapy plus chemotherapy.